CT-INTERACTIVE-BROKERS
28.2.2022 16:02:07 CET | Business Wire | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the launch of Traders’ Insight Radio , a new podcast series featuring interviews with executives, thought leaders and market experts from across the financial services industry discussing topical themes impacting global markets and trading. Listeners familiar with Traders’ Insight , Interactive Brokers’ online resource for market commentary, will recognize in-house IBKR podcast hosts providing important context around the singular viewpoints being examined during the conversations.
Intended for a broad audience including both advanced traders and novice investors, Traders’ Insight Radio explores a wide range of interesting topics for any investor and enhances the suite of offerings already available through IBKR Campus , the company’s best-in-class educational resource. Recent and upcoming podcasts will feature conversations on the impact of artificial intelligence (AI) on markets, opportunities in foreign securities and views on cryptocurrency as the new digital asset class. For retail investors just starting out or advanced traders seeking to expand their knowledge base, IBKR Campus includes courses and content on trading, markets and current events, as well as overviews dedicated to IBKR’s products and trading platforms – and now, notable podcast interviews.
“We continue to focus on providing investors with the educational tools needed to improve their understanding of financial markets and trading,” said Steve Sanders, EVP of Marketing and Product Development at Interactive Brokers. “Traders’ Insight Radio complements the resources already available through IBKR Campus and is a new and entertaining way all investors can easily access and benefit from expertise across the finance industry.”
The series was introduced in January and early episodes include a two-part interview with Thomas Peterffy, Founder and Chairman of Interactive Brokers Group, discussing his early trading days as an options market maker and how he successfully introduced technology to the trading floor. Listeners will benefit from Mr. Peterffy’s perspective on a variety of subjects such as cryptocurrency, monetary policy and the impact of rising rates and inflation on the economy, while hearing anecdotes from his storied career. To listen to Mr. Peterffy’s podcast interviews, please visit:
Part 1: "You Mean You Don't Have to Know Anything to Do This?"
Part 2: "Mr. Sosnick, I Do Find You Increasingly Useless"
The latest episodes of Traders’ Insight Radio are available for free on the Traders’ Insight blog, through Interactive Brokers’ trading platforms including Trader Workstation, Client Portal and IBKR Mobile and popular podcasting services including Apple Podcast, Google Podcast, Podbean and Spotify.
For the full suite of free IBKR Campus resources, please see below and visit ibkr.com/campus .
Traders' Academy : Investors can improve their understanding of the products, tools and markets available through Interactive Brokers’ Trader Workstation, Client Portal, IBKR Mobile and TWS API applications.
IBKR Webinars : Investors can watch, listen and learn about current market topics and IBKR tools through live and recorded webinars.
Traders' Insight : Investors can watch, read or listen to market commentary from more than 70 industry professionals, including the new Traders’ Insight Radio.
IBKR Quant : A blog intended for quantitative professionals with an interest in programming, deep learning, IBKR API, AI, Blockchain and other transformative technologies influencing modern markets.
Student Trading Lab : A free online resource for educators looking to blend finance or computer science classwork with real-world trading experience.
About Interactive Brokers Group, Inc.:
Interactive Brokers Group affiliates provide automated trade execution and custody of securities, commodities and foreign exchange around the clock on over 135 markets in numerous countries and currencies, from a single IBKR Integrated Investment Account to clients worldwide. We service individual investors, hedge funds, proprietary trading groups, financial advisors and introducing brokers. Our four decades of focus on technology and automation has enabled us to equip our clients with a uniquely sophisticated platform to manage their investment portfolios. We strive to provide our clients with advantageous execution prices and trading, risk and portfolio management tools, research facilities and investment products, all at low or no cost, positioning them to achieve superior returns on investments. Barron’s ranked Interactive Brokers #1 with 5 out of 5 stars in its February 26, 2021, Best Online Broker Review.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223006298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom